Table of Contents Table of Contents
Previous Page  10 / 27 Next Page
Information
Show Menu
Previous Page 10 / 27 Next Page
Page Background

Lu S. et al. CSCO 2017

Treatment-Related Select AEsa in

Nivolumab-Treated Patients

(Checkmate 017 and 057 3-Year Update; Pooled Analysis)

Nivolumab

(N = 418)

Any grade

Grade 3−4

Overall, %

37.1

4.8

Skin

16.3

1.0

Gastrointestinal

9.1

1.2

Endocrine

8.6

0

Hepatic

5.7

1.0

Pulmonary

4.5

1.4

Renal

2.6

0.2

Hypersensitivity/infusion reaction

2.4

0

a

Select AEs are those with potential immunologic etiology that require frequent monitoring/intervention

b

Includes events reported between first nivolumab dose and 30 days after last nivolumab dose

There was 1 new grade 3–4 treatment-related select AE of interstitial lung disease with nivolumab

between 2 and 3 years